YoheiDoiMD
Infectious Disease • Pittsburgh, PAAssistant Professor, Medicine, University of Pittsburgh School of Medicine
Are you Dr. Doi?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3601 5th Ave
"# Falk"
Pittsburgh, PA 15213Phone+1 412-648-6401Fax+1 412-648-6399
Summary
- Dr. Yohei Doi, MD is an infectious disease specialist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania. He is an Assistant Professor at University of Pittsburgh School of Medicine.
Education & Training
Nagoya University - School of MedicineClass of 1998
Certifications & Licensure
PA State Medical License 2005 - 2026- PA State Medical License 2008 - 2026
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Publications & Presentations
PubMed
- Ensitrelvir treatment-emergent amino acid substitutions in SARS-CoV-2 3CLdetected in the SCORPIO-SR phase 3 trial.Takeki Uehara, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Masaya Yamato
Antiviral Research. 2025-04-01 - A case of fatal disseminated infection with masticator space abscess caused by ESBL-producing K57-ST412 hypervirulent Klebsiella pneumoniae.Kohei Ukai, Yoshitaka Tomoda, Satoe Ishii, Satoshi Nakazato, Yohei Doi
Journal of Infection and Chemotherapy. 2025-03-01 - Phenotypic and in silico characterization of carbapenem-resistant Serratia marcescens clinical strains.Anelise Stella Ballaben, Otávio G G de Almeida, Joseane Cristina Ferreira, Doroti de Oliveira Garcia, Yohei Doi
Journal of Global Antimicrobial Resistance. 2025-02-19
Press Mentions
Fujita Health University Favipiravir Trial Evidences No Statistically Conclusive Benefit to COVID-19 Patients: A Question Mark for Favipiravir?July 11th, 2020- WHO Studies File International Each Day Coronavirus Circumstances Improve: LiveJuly 10th, 2020
No Pause in Coronavirus Trial for Avigan, Japan's Lead Researcher SaysMay 20th, 2020- Join now to see all
Grant Support
- Colistin resistance in extensively drug-resistant Gram-negative pathogensUNIVERSITY OF PITTSBURGH AT PITTSBURGH2014–2025
